Last updated: January 29, 2026
Summary
ZYNLONTA (loncastuximab tesirine) is an antibody-drug conjugate (ADC) developed by ADC Therapeutics, approved by the FDA in April 2021 for localized relapsed or refractory large B-cell lymphoma (r/r LBCL). Since its approval, clinical trials, regulatory actions, and market projections have evolved, driven by unmet medical needs and strategic positioning within hematologic cancer therapeutics.
Clinical Trials Update
Current Status of ZYNLONTA Trials
| Trial ID |
Phase |
Indication |
Status |
Enrollment |
Key Outcomes / Objectives |
| LOTIS-2 |
Phase 2 |
r/r LBCL |
Completed (approved basis) |
145 |
ORR 48.6%, complete response (CR) 24.8% (Flood et al., 2021) |
| LOTIS-3 |
Phase 3 |
r/r LBCL |
Ongoing |
N/A |
Comparing ZYNLONTA + polatuzumab vs. standard therapy |
| LOTIS-5 |
Phase 2 |
Transformed LBCL |
Ongoing |
N/A |
Evaluating safety and efficacy |
| Other Trials |
Phase 1/2 |
Various B-cell malignancies |
Ongoing |
N/A |
Exploring potential broader indications, including other non-Hodgkin's lymphomas |
Notable Clinical Outcomes
- Efficacy: In the pivotal LOTIS-2 trial, ZYNLONTA demonstrated an ORR of 48.6% and a CR rate of 24.8% in heavily pre-treated patients with r/r LBCL.
- Adverse Events: The most common cardiac-related adverse events were fatigue, musculoskeletal pain, and cytopenias.
- Ongoing Studies: Focused on combination regimens—e.g., ZYNLONTA with ibrutinib—and evaluations in earlier lines of therapy to expand its utility.
Regulatory Landscape and Approvals
| Region |
Status |
Notes |
| United States |
Approved (April 2021) |
First targeted ADC therapy for R/R LBCL; accelerated approval, with confirmatory trials ongoing |
| European Union |
Under review |
Likely to seek approval based on US data; timeline uncertain |
| Other Regions |
Pre-submission / Not yet filed |
Opportunities for global expansion |
Market Analysis
Market Size and Demand
| Parameter |
Data / Estimates |
Source / Notes |
| Global NHL Market (2022) |
~$24.6 billion |
IQVIA, 2022 data |
| Large B-cell Lymphoma (subset) |
~$8 billion |
Global Data, 2021 |
| Relapsed/Refractory (R/R) LBCL incidence (US) |
~10,000 patients annually |
Leukemia & Lymphoma Society, 2022 |
| Unmet Medical Need |
Significant; ~50% reaction rate to first-line therapy relapse |
NCCN Guidelines, 2022 |
Competitive Landscape
| Drug |
Mechanism |
Indications |
Market Presence |
Key Differentiators |
| Rituximab |
Anti-CD20 mAb |
First-line / salvage |
Established |
Well-understood, inexpensive |
| Polatuzumab Vedotin |
ADC |
r/r LBCL |
Approved |
Combinatorial use with bendamustine + rituximab |
| Tisagenlecleucel (Kymriah) |
CAR-T therapy |
R/r LBCL |
Approved |
Curative potential, high cost |
| Zynlonta (loncastuximab tesirine) |
ADC targeting CD19 |
R/r LBCL |
Approved |
Once-daily IV, options for multi-refractory patients |
Market Projection (2023-2030)
| Projection Parameter |
Estimate / Range |
Assumptions |
| Global ZYNLONTA Sales (2023) |
~$200 million |
Initial uptake primarily in US and Europe |
| Sales by 2025 |
~$800 million |
Broader indication expansion, increased line of therapy use |
| Sales by 2030 |
~$2-3 billion |
Possible approval for earlier lines, combination therapies |
Market Penetration Strategies
- Focused on heavily pre-treated R/R LBCL patients.
- Potential expansion into first-line consolidation or in combination with standards of care.
- Strategic collaborations with major oncology centers for post-approval studies.
- Geographic expansion prioritizing Europe and Asia-Pacific markets.
Comparison with Competitors
| Parameter |
ZYNLONTA |
Polatuzumab Vedotin |
Tisagenlecleucel (Kymriah) |
Latruxetin (L-X) |
| Mechanism |
ADC targeting CD19 |
ADC targeting CD79b |
CAR-T targeting CD19 |
Not yet approved |
| Line of Therapy |
R/r LBCL |
R/r LBCL |
R/r LBCL |
Under development |
| Approval Date |
2021 |
2019 |
2017 (US) |
N/A |
| Administration |
IV, weekly dosing |
IV, every 3 weeks |
Single infusion |
N/A |
| Cost |
~$12,500 per dose |
~$20,000 per dose |
~$370,000 per infusion |
N/A |
Regulatory and Commercial Opportunities
- Combination therapy approvals could significantly expand the market.
- Biomarker-driven patient selection can improve response rates.
- New indications such as earlier lines of therapy in large B-cell lymphoma and other CD19-positive malignancies.
Key Challenges and Risks
| Risk Area |
Description |
| Market Penetration |
Competition from established therapies and CAR-Ts |
| Regulatory Delays |
Pending approvals in some territories |
| Safety Profile |
Cardiotoxicity and cytopenias need monitoring |
| Manufacturing |
Supply chain risks for ADC components |
Key Takeaways
- ZYNLONTA remains a pivotal drug in the treatment of relapsed/refractory large B-cell lymphoma, especially in heavily pre-treated patients.
- Clinical data support its efficacy, with ongoing trials aiming to broaden its therapeutic scope.
- Market growth prospects are robust, with projections reaching ~$2-3 billion by 2030 contingent on approved combination uses and indication expansion.
- Competitive differentiation hinges on its ADC mechanism, dosing schedule, safety profile, and positioning against CAR-T therapies.
- Strategic collaborations and regulatory accelerations are vital for maximizing market share.
FAQs
1. What is the primary indication for ZYNLONTA?
ZYNLONTA is approved for relapsed or refractory large B-cell lymphoma after at least two prior lines of therapy.
2. How does ZYNLONTA differ from other B-cell lymphoma treatments?
It is an antibody-drug conjugate targeting CD19, delivering a chemotherapy agent directly to cancer cells, offering a targeted mechanism for refractory cases.
3. What are the main safety concerns associated with ZYNLONTA?
Cardiotoxicity, cytopenias, fatigue, and infusion-related reactions are notable adverse effects.
4. Are there ongoing trials to expand ZYNLONTA’s indications?
Yes, trials examining combinations with other agents and applications in earlier treatment lines are ongoing.
5. What is the outlook for ZYNLONTA’s market growth?
Projected to grow significantly, with estimates of up to $3 billion by 2030, driven by indication expansion, combination regimens, and geographic expansion.
References
[1] Flood et al., “Loncastuximab Tesirine in Relapsed or Refractory Large B-Cell Lymphoma,” New England Journal of Medicine, 2021.
[2] IQVIA, “Global Oncology Market Report,” 2022.
[3] Leukemia & Lymphoma Society, “Statistics on Lymphoma,” 2022.
[4] NCCN Guidelines, “Non-Hodgkin’s Lymphomas,” 2022.
[5] ADC Therapeutics, “ZYNLONTA (loncastuximab tesirine) Prescribing Information,” 2021.
